Administration of Immune Globulin Associated With Aseptic Meningitis

Kato, Eiji; Shindo, Shoichiro; Eto, Yoshiharu; Hashimoto, Nobuo; Yamamoto, Masashi; Sakata, Y; Hiyoshi, Y

doi:10.1001/jama.1988.03720220017011

Cited by 52 publications

(10 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The first association with IGIV therapy was reported in 1988 [10]. At least 30 patients have now been reported in the English literature to have developed aseptic meningitis associated with IGIV therapy [4,[10][11][12][13][14][15][16][17][18][19][20][21][22][23][24][25][26][27][28][29].…”

Section: Aseptic Meningitismentioning

confidence: 99%

“…The majority of patients who have developed aseptic meningitis did so during the first cycle of IGIV therapy or within 24 h after completing an infusion. Recurrence of symptoms can occur with reinfusion [10,13]. When performed in patients at the onset of symptoms, lumbar punctures typically demonstrate pleocytosis, usually with a predominance of neutrophils.…”

Section: Aseptic Meningitismentioning

confidence: 99%

See 1 more Smart Citation

Adverse events associated with intravenous immunoglobulin therapy

Hamrock

2006

International Immunopharmacology

147

136

View full text Add to dashboard Cite

Section: Aseptic Meningitismentioning

confidence: 99%

Section: Aseptic Meningitismentioning

confidence: 99%

Adverse events associated with intravenous immunoglobulin therapy

Hamrock

2006

International Immunopharmacology

147

136

View full text Add to dashboard Cite

“…Acute aseptic meningitis, better described as meningism, has complicated the use of high dose IVIG in a few isolated patients with ITP and chronic inflammatory demyelinating polyneuropathy (Casteels-Van Daele et al 1990;Kato et al 1988;Ramirez et al 1992;Rao et al 1992). Seven patients have been reported who developed headache, vomiting and nuchal rigidity 10 hours to 7 days after an infusion of high dose IVIG.…”

Section: Neurologicalmentioning

confidence: 99%

Adverse Effects of Intravenous Immunoglobulin

1993

View full text Add to dashboard Cite

The range of diseases in which intravenous immunoglobulin (IVIG) is effective has expanded significantly since its initial use in primary antibody deficiency. There are at present at least 17 preparations of IVIG in use worldwide with similar profiles of adverse effects. Infusion-related effects range in severity. Mild adverse reactions (headache, flushing, low backache, nausea, wheezing) are often associated with a fast infusion rate, and respond rapidly on slowing the infusion. Very rare episodes of life-threatening anaphylaxis may occur, particularly in those IgA-deficient patients with anti-IgA antibodies; such patients should receive an IgA-depleted preparation of IVIG. There are concerns with any blood product about safety in regard to viral transmission. The 4 outbreaks of non-A non-B hepatitis (probably hepatitis C) in the 1980s were associated with the use of particular batches of IVIG. The more recent exclusion of all anti-hepatitis C virus positive individuals from the donor pool, and the introduction of specific antiviral steps in the manufacture of IVIGs, should prevent further outbreaks. The human immunodeficiency virus (HIV) is effectively inactivated during the manufacturing process itself and HIV transmission has not been reported with IVIG. Rarely, haematological (Coombs' test positive haemolysis), neurological (aseptic meningitis) or renal (transient rises in serum creatinine) adverse effects may be seen when high doses of IVIG are used for immunomodulatory purposes. Haemolysis, due to passive transmission of blood group antibodies (anti-A, anti-D), may be prevented by selecting IVIG batches that give a negative cross-match between the recipient's red cells and IVIG.(ABSTRACT TRUNCATED AT 250 WORDS)

show abstract

“…The globulin is a purified protein fraction from human plasma; administration to patients with idiopathic thrombocytopenic purpura or Kawasaki disease has sometimes resulted in anaphylaxis or other allergic reactions. 19,20 The present case suggests that γ-globulin might also be able to cause a drug-induced hypersensitivity syndrome. However, it was ultimately difficult to elucidate which component of γ-globulin was responsible.…”

Section: Discussionmentioning

confidence: 70%